Business Context and Reporting Period
Evaxion A/S, a clinical-stage TechBio company specializing in AI-Immunology powered vaccines, filed this Form 6-K on November 12, 2025. The filing covers the month of November 2025 and primarily serves to incorporate a press release regarding the company's 2026 financial calendar.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a procedural filing to announce a calendar update rather than a financial results report.
Material Changes
No material financial changes versus the prior comparable period are disclosed in this document. The filing focuses solely on the announcement of the 2026 financial calendar.
Guidance, Outlook, and Management Commentary
Management, represented by Interim Chief Executive Officer Birgitte Rønø, announced the 2026 financial calendar via a press release furnished as Exhibit 99.1. The filing does not contain specific financial guidance, risk factors, or details on contingencies beyond the calendar announcement.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for the specific dates of the 2026 financial calendar.
- Verify the status of the interim CEO appointment and any related governance updates.
- Check subsequent filings for the next scheduled financial results based on the newly announced calendar.